Search Investigator-sponsored research Healthcare Professionals INVESTIGATOR-SPONSORED TRIALS (IST) Program Description Our Investigator-Sponsored Trials (IST) program provides support for external clinical research that advances medical and/or scientific knowledge about our products and clinical candidates to enhance patient care. Our current IST portfolio includes programs investigating: Brentuximab vedotin Enfortumab vedotin Tucatinib The objective of our IST program is to provide funding and/or study drug for clinical research that will: Address unmet medical needs with new scientific data Support pilot studies that explore the feasibility of new investigational treatments To discuss your proposed research or for questions about our process, please contact your regional Medical Science Liaison (MSL) or email us at IST@seagen.com for help identifying the MSL in your region. Innovation to Achieve Equity in Cancer Care IST Seagen is committed to improving the lives of people with cancer through innovative therapies in a diverse, equitable and inclusive manner. Recognizing that cancer health disparities persist, to achieve our mission of making meaningful differences in the lives of people with cancer, we are inviting you to propose and submit a concept to research actionable solutions to address health disparities. Please click here for a complete description of the RFP. Please click here to access the portal for concept submission. Process Outline Concepts are accepted on an ongoing basis via our online portal. The regional MSL will present the proposal to the Investigator-Sponsored Trial Review Committee (ISTRC). If accepted, a full protocol and budget is requested within 90 days, which will be reviewed by the ISTRC. Following ISTRC approval, start-up regulatory and contracting activities may begin. For a detailed description of our program, processes, and applicant responsibilities, click Program Overview. Program Overview Application and Questions To apply for an IST related to brentuximab vedotin, tucatinib, or enfortumab vedotin (Canada only), please visit our online portal. Online Portal Online Portal FAQ To apply for an IST related to enfortumab vedotin research (United States only), please visit the Astellas Investigator-Sponsored Research portal. Enfortumab vedotin proposals are reviewed jointly by Seagen and Astellas. Please email IST@seagen.com with questions about our IST program. TRANSLATIONAL RESEARCH AGREEMENTS (TRA) Program Description Our Translational Research Agreement (TRA) program provides support for non-clinical research projects. Requests for materials transfer or sponsored research will be considered, with a limited number of projects supported each year. To discuss your proposed research or for questions about our process, please contact your regional Medical Science Liaison (MSL) or email us at translationalresearch@seagen.com for help identifying the MSL in your region. Process Outline Project will be reviewed within 90 days and the regional MSL will present the proposal internally. For questions regarding our process, email us at translationalresearch@seagen.com. Application and Questions To apply for a TRA related to available programs and for enfortumab vedotin (Canada only), register via our online portal. Online Portal Online Portal FAQ To apply for a TRA related to enfortumab vedotin research (United States only), please visit the Astellas Investigator-Sponsored Research portal. Enfortumab vedotin proposals are reviewed jointly by Seagen and Astellas. Please email translationalresearch@seagen.com with questions about our TRA program. Access scientific and clinical resources Healthcare professionals in the United States can access recent congress presentations, videos about our science, and more on our medical affairs website. Explore the Medical Affairs Website Patients and Caregivers Diseases We Study Real Stories Clinical Trials Support and Resources Healthcare Professionals Medical Information Clinical Data Requests Investigator-Sponsored Research Medical Education Grants Site Map Contact Us FAQs Sign up for updates This website is intended for U.S. residents only. ©2021 Seagen Inc. Privacy Policy Terms and Conditions Social Media Terms > Cookie Notification By continuing to browse the site, you agree to accept our use of cookies. For more information, please review our Cookies Policy. Accept